Sulphydryl containing drugs, such as cysteamine, have been shown to protect in vivo against acute gastric mucosal injury caused by ethanol,' indomethacin,' and endogenous agents released by exposure to cold and restraint stress.3 Gastric vascular endothelium has been reported to be the target of the protective effect afforded by sulphydryl compounds in vivo.45 It is not known whether sulphydryl containing drugs protect gastric epithelial cells directly without the mediation of vascular or other systemic factors against damage brought about by sodium taurocholate and indomethacin.
Several agents, such as histamine H2 receptor antagonists and omeprazole,67 protect against damage to the cell membranes by taurocholate, but only prostaglandins have been found capable of protecting against agents that alter internal cellular metabolism such as indomethacin.8 I The role of endogenous prostaglandins in the protection of gastric mucosa by sulphydryl containing drugs is unclear. 1011 The effect of cysteamine on prostaglandin E2 (PGE2), production by gastric epithelial cells is unknown.
The aims of the present study were (1) to evaluate whether the sulphydryl agent cysteamine protects gastric epithelial cell monolayers against damage brought about by sodium taurocholate and indomethacin in vitro in conditions independent of vascular, neural, and hormonal factors; (ii) to evaluate the effect of cystamine on PGE2 production by gastric cells using monolayers derived from a well differentiated human gastric cell line, MKN 28.12 The MKN 28 cell line has been shown to be an effective model for the study of drug induced damage to and protection oft gastric cells in vitro giving results comparable with those for monolayers ofhuman gastric epithelial cells in primary cultures derived from surgical specimens."3
Methods

MATERIALS
The characteristics of the MKN 28 cell line have been described.'213 Culture medium was a 1:1 mixture of Dulbecco's modified Eagle medium (DME) and Ham's nutrient F-12 medium (F-12 medium) (both from Gibco, Grand Island, NY) supplemented with 15 mmol/l N-hydroxyethylpiperazine-N-ethane sulphonic acid (Hepes) buffer (Sigma Chemical, St Louis, MO), 1 2 g/l NaHCO3 (Sigma), heat inactivated (at 56°C for 30 min) 10% fetal bovine serum (Armour Pharmaceutical, Kankakee, IL), and 1% antibiotic-antimycotic solution, 100 pJml penicillin, 100 [tg/ml streptomycin, 0 25 pg/ml amphotericin B (Irvine Scientific, Santa Ana, CA). Sodium taurocholate, cysteamine, indomethacin, iodoacetamide, monochloroacetic acid, reduced glutathione, cysteine, and ethylenediamine tetra-acetic acid (EDTA) were purchased from Sigma. Taurocholate, cysteamine, and iodoacetamide were dissolved in DME-F12 medium, pH was adjusted to 7-4, and drugs were used immediately. Indomethacin 50 mmol/l was freshly prepared, obtained by dissolving the drug in 0-2 mol/l Na2CO3 pH was adjusted to 7-4 by adding 5 mol/l NaH2PO4. This solution was diluted in DME-F12 medium to reach the desired concentration and the solution was used immediately. 5"Chromium (5'Cr) (sodium chromate 200-900 Ci/g chromium) and trypsin were from ICN Biomedicals, Irvine, CA. 5 and 6 ). Cysteamine 10 mmol/l, the level at which maximum protection occurred, decreased taurocholate or indomethacin induced specific 51Cr release from (mean (SEM)) 28-9 (2)% to ( decrease of cell damage, p<001) and from 31'9 (1)% to not give protection, we also tested the effect of cysteamine on cell damage induced by higher doses of taurocholate or indomethacin. Cysteamine 10 and 20 mmol/l decreased 15 mmol/l taurocholate induced specific 5Cr release from 74-5 (1)% to 65-8 (2)% (8-7 point reduction equal to 12% decrease of cell damage, p<001) and to 62-7 (1)% (11L8 point reduction, equal to 16% decrease of cell damage, p<0 01), respecttively (Fig 7) . Cysteamine did not give appreciable protection against damage induced by indomethacin 7 sulphydryl production, we evaluated the effect of the prostaglandin synthesis inhibitor indomethacin and the sulphydryl blocker iodoacetamide on the protection given by cysteamine. Indomethacin 10-to 10-4mol/l decreased PGE2 production by cultured cells in a dose dependent **1 ** ** manner (Fig 8) . The concentration of indomethacin 10' mol/l reduced PGE2 production by cultured cells by 60%. The cellular content of non-protein glutathione and non-protein non-protein glutathione in MKN 28 cells (Fig 9) . Pretreatment with the prostaglandin synthesis inhibitor indomethacin in the concentration of 10' mol/l did not prevent the protection given by cysteamine (Figs 10 and 11 ). On the contrary, the sulphydryl blocker agent iodoacetamide significantly prevented the protection afforded by cysteamine 10 mmol/l. Neither cysteamine (10 mmol/1), indomethacin (10-' mol/l), nor iodoacetamide (0 1 mmol/l) produced significant cell damage. theless, because indomethacin did not completely inhibit PGE2 production, it cannot be concluded that protection of gastric mucosal cells by cysteamine in vitro is completely independent of prostanoid production. It is possible that a certain amount of prostaglandin is required for sulphydryls to exert their protective effect. 28 Unfortunately, in this and other3>32 in vitro gastric cell models indomethacin cannot further decrease PGE2 levels without causing cell damage.
Cysteamine is not the first agent that has been found to exert a protective action on gastric epithelial cells without enhancing prostaglandin production. Protection by cimetidine, ranitidine,6 and omeprazole7 against taurocholate induced damage to gastric mucosal cells was not associated with any change in prostaglandin production. On the other hand, somatostatin, which did not protect against taurocholate damage in vitro significantly increased prostaglandin production. 33 Suggestive evidence that protection by cysteamine in this study is specifically related to endogenous sulphydryl groups is that the sulphydryl blocker iodoacetamide, in a concentration which decreased by more than 50% the cellular levels of non-protein sulphydryls (without affecting cell viability), significantly prevented the protective effect of cysteamine. It Our findings show that (i) the sulphydryl compound cysteamine directly protects gastric epithelial cells in vitro (ii) this protection is against a drug which inhibits prostaglandin production (indomethacin) and one whose damaging effect is not associated with interference with prostanoid metabolism (taurocholate), (iii) cysteamine protection in vitro occurs despite inhibition of PGE2 synthesis (iv) seems to be directly related to the activity of its sulphydryl group possibly against toxic oxygen radicals.
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